Ekkehart Paditz

Prof. Dr. Ekkehart Paditz

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in APL Photonics
Verified
Journal Article
Open access
PDF file
VVV. B. Verma
V. B. Verma
BKB. Korzh
B. Korzh
AWA. B. Walter
A. B. Walter
ALA. E. Lita
A. E. Lita
RBR. M. Briggs
R. M. Briggs
MSM. D. Shaw
M. D. Shaw
We developed superconducting nanowire single-photon detectors based on tungsten silicide, which show saturated internal detection efficiency up to a wavelength of 10 μm. These detectors are promising for applications in the mid-infrared requiring sub-nanosecond timing, ultra-high gain stability, low dark counts, and high efficiency, such as chemical sensing, LIDAR, dark matter searches, and exoplanet spectroscopy.

29 September 2024 in Children
Verified
Journal Article
Open access
PDF file
Ekkehart PaditzEkkehart Paditz
Ekkehart Paditz
Introduction: According to current knowledge, at birth, the pineal gland and melatonin receptors are already present and the suprachiasmatic nucleus is largely functional, and noradrenaline, the key pineal transmitter, can be detected in the early foetal period. It is still unclear why the pineal gland is not able to start its own pulsatile synthesis and secretion of melatonin in the first months of life, and as a result, infants during this time are dependent on an external supply of melatonin. Method: The causes and consequences of this physiological melatonin deficiency in human infancy are examined in a systematic review of the literature, in which 40 of 115 initially selected publications were evaluated in detail. The references of these studies were checked for relevant studies on this topic. References from previous reviews by the author were taken into account. Results: The development and differentiation of the pineal gland, the pinealocytes, as the site of melatonin synthesis, and the development and synaptic coupling of the associated predominantly noradrenergic neural pathways and vessels and the associated Lhx4 homebox only occurs during the first year of life. Discussion: The resulting physiological melatonin deficiency is associated with sleep disorders, infant colic, and increased crying in babies. Intervention studies indicate that this deficiency should be compensated for through breastfeeding, the administration of nonpooled donor milk, or through industrially produced chrononutrition made from nonpooled cow’s milk with melatonin-poor day milk and melatonin-rich night milk.

24 April 2024 in Somnologie
Verified
Journal Article
Open access
PDF file
Ekkehart PaditzEkkehart Paditz
Ekkehart Paditz
The effectiveness of melatonin in nonorganic sleep disorders in children and adolescents has been examined in 33 randomised controlled studies [1]. This review presents the current state of knowledge on the physiology, pharmacokinetics, pathophysiology and toxicity of melatonin in infancy based on well-documented studies. Up to the third month of life, premature and full-term babies cannot produce their own melatonin, so they are dependent on exogenous supply via their own mother’s breast milk, non-pooled breast milk or non-pooled formula. Non-pooled means that a distinction should be made between melatonin-rich night milk and melatonin-poor day milk. A number of intervention studies indicate that administration of melatonin to infants may have analgesic and antioxidant effects related to ophthalmological examinations, prevention of bronchopulmonary dysplasia, and the treatment of hypoxic ischaemic encephalopathies. Since melatonin concentrations in the mother’s blood, in breast milk and, e.g., also in cow’s milk show regular day–night fluctuations, and since breastfed infants have a more stable melatonin supply and fewer sleep disorders, infants who cannot be breastfed by their own mother should preferably have chrononutrition made from non-pooled human or cow’s milk. There has recently been evidence that infantile colic is a disorder with delayed development of chronobiological rhythms.

13 November 2023 in Monatsschrift Kinderheilkunde
Verified
Journal Article
Open access
PDF file
Ekkehart PaditzEkkehart Paditz
Ekkehart Paditz
Zusammenfassung Stand der Forschung Bisher liegen 33 randomisierte kontrollierte Studien (RCT) unterschiedlicher Qualität zu den Effekten oraler Melatoningaben im Vergleich zu Placebo bei Kindern und Jugendlichen im Alter von 2 bis 18 Jahren vor; diese werden in der vorliegenden Übersicht in Bezug auf Diagnosegruppen vorgestellt. Zusätzlich existieren zu einigen Erkrankungen Fallbeschreibungen oder -serien. Hinweise zur Verordnung Aus diesen klinischen Daten werden orientierende Empfehlungen zur Dosierung, zum Applikationszeitpunkt und zur Behandlungsdauer abgeleitet. Auf den aktuellen Stand der Zulassungen in Deutschland, Österreich und der Schweiz (D-A-CH) wird hingewiesen. Nebenwirkungen und Komplikationen Möglichst niedrige Dosierungen und mehrwöchige Auslassversuche werden empfohlen, damit ein Resetting der Melatoninrezeptoren erfolgen kann. Bisher sind keine ausreichenden Daten zu Langzeiteffekten, die sich u. a. auch auf die Auslösung der Pubertät beziehen könnten, verfügbar. Des Weiteren wurde kürzlich über Todesfälle bei Säuglingen und Kleinkindern im zeitlichen Zusammenhang mit erheblichen Melatoninüberdosierungen berichtet. Differenzialdiagnostik vorab Vor Behandlungsbeginn sollten eine ausführliche Anamnese und ein neurologischer Status erhoben werden (insbesondere bezüglich Sehstörungen, Kopfschmerzen, Schwindel, Polyurie, Polydipsie), damit klinisch bedeutsame Pinealiszysten, Pinealistumoren und supraselläre Tumoren nicht übersehen werden.

16 May 2025 in Children
Verified
Journal Article
Open access
PDF file
Ekkehart PaditzEkkehart Paditz
Ekkehart Paditz
Bertold RennerBertold Renner
Bertold Renner
RKRainer Koch
Rainer Koch
BSBarbara M. Schneider
Barbara M. Schneider
ASAngelika Schlarb
Angelika Schlarb
OIOsman S. Ipsiroglu
Osman S. Ipsiroglu
Background: To date, it remains unclear which oral doses and preparation forms of melatonin should be recommended for children and adolescents with non-organic sleep disorders and autism spectrum disorder (ASD). We reviewed the current state of knowledge on this topic based on randomised placebo-controlled trials (RCTs) and diagnosis-related blood melatonin concentrations available in this age group. Method: Two investigators independently searched PubMed, PsycINFO, MEDLINE, and Cochrane CENTRAL on 1 March 2025 for the keywords “melatonin”, “autism”, and “randomised” in titles and abstracts in all languages, including an evaluation of the references of the reviews, systematic reviews, and meta-analyses published up to that date, some of which were based on searches in numerous databases. Based on this, additional in-depth searches were carried out in PubMed for pharmacokinetic, physiological, and pathophysiological data on melatonin in children and adolescents, with a special focus on ASD. Results: To date, five RCTs on non-organic sleep disorders in children and adolescents with the sole diagnosis of ASD or with subgroup analyses in the presence of several initial diagnoses such as ADHD, epilepsy, Smith–Magenis, or Fragile X syndrome are available. In these studies, rapid-release, non-delayed preparations were administered orally. In one of these studies, the clinical efficacy of a combination preparation with a sustained-release and a non-released active substance component was tested. Pharmacokinetic data with multiple determinations of melatonin concentrations in the blood are only available for children with ASD in the form of a case series (N = 9). Discussion: RCTs comparing the efficacy of delayed melatonin preparations with non-delayed rapid-release oral preparations are not yet available. Physiological data and clinical effects documented in five RCTs indicate that non-delayed melatonin preparations with an initial rapid onset of action are effective for non-organic sleep disorders in children and adolescents with ASD. Conclusions: From a clinical, pharmacokinetic, and physiological point of view, the RCTs available to date and the data on melatonin concentrations in the blood of children with ASD, measured several times over 24 h, suggest that a low oral melatonin dose and a non-delayed preparation with rapid onset should be started in children and adolescents with non-organic sleep disorders in ASD, if sleep hygiene advice and psychotherapeutic interventions have not demonstrated sufficient effects.

16 August 2022 in Somnologie
Verified
Journal Article
Open access
PDF file
Ekkehart PaditzEkkehart Paditz
Ekkehart Paditz
AWAlfred Wiater
Alfred Wiater
OIOsman S. Ipsiroglu
Osman S. Ipsiroglu
MQMirja Quante
Mirja Quante
SMSilvia Müller-Hagedorn
Silvia Müller-Hagedorn
CPChristian F. Poets
Christian F. Poets